Conformis Inc.05.28.20
Conformis Inc. announced today that it has entered into a settlement and license agreement with Zimmer Biomet Holdings Inc., Zimmer Inc., Zimmer U.S. Inc., and Biomet Manufacturing LLC (together, Zimmer Biomet) that resolves all patent disputes between the companies.
“We are glad to have reached a mutually productive settlement of all current patent litigation with Zimmer Biomet and are pleased to have the company become a licensee,” said Mark Augusti, president and CEO. “Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our core business of patient-specific implants.”
The settlement comes four months after the company achieved the milestone of 100,000 knee joint replacement implants. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy.
“We are very pleased to announce this tremendous milestone for personalized joint replacement implant treatments,” Augusti said in January. “We are strong advocates for the utilization of patient-specific implants in total knee replacement because the size, shape and curvature of the knee are unique for each patient. Implants designed specifically for each patient enable efficient surgery and higher levels of patient satisfaction versus standard ‘off-the-shelf’ implants. Thank you to all of the surgeons and patients who have traveled this journey with us and helped achieve this significant milestone.”
More than 20 peer-reviewed clinical studies published in medical journals to date support the strong performance of Conformis technology. Links to these medical journals are available here. In 2018, Conformis engaged PrecisionEffect and SurveyHealthcareGlobus (SHG) to conduct a study of patient satisfaction with knee implants – Conformis vs. non-Conformis. The results of this third-party study show that 87 percent of the Conformis patients surveyed were highly likely to recommend their knee implant to a friend or colleague, versus only 70 percent of the non-Conformis patients surveyed.
In November 2019, the company announced U.S. Food and Drug Administration clearance of the new 3D-designed Conformis Hip System and the system’s full commercial launch. Similar to the design process for Conformis knee technologies, the Conformis Hip System uses proprietary advanced imaging and design software, to deliver a patient-specific, pre-operative surgical plan with a comprehensive set of iJig instruments and patient-matched implants. The Conformis Hip System iJigs work in conjunction with anatomic landmarks to ensure the proper placement and orientation of the femoral stem, as well as the acetabular cup. In addition, Conformis’ proprietary reamer system provides a single-use, patient-matched reaming solution that delivers efficient and accurate cup orientation to a controlled depth for each surgical case.
“We are glad to have reached a mutually productive settlement of all current patent litigation with Zimmer Biomet and are pleased to have the company become a licensee,” said Mark Augusti, president and CEO. “Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our core business of patient-specific implants.”
The settlement comes four months after the company achieved the milestone of 100,000 knee joint replacement implants. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy.
“We are very pleased to announce this tremendous milestone for personalized joint replacement implant treatments,” Augusti said in January. “We are strong advocates for the utilization of patient-specific implants in total knee replacement because the size, shape and curvature of the knee are unique for each patient. Implants designed specifically for each patient enable efficient surgery and higher levels of patient satisfaction versus standard ‘off-the-shelf’ implants. Thank you to all of the surgeons and patients who have traveled this journey with us and helped achieve this significant milestone.”
More than 20 peer-reviewed clinical studies published in medical journals to date support the strong performance of Conformis technology. Links to these medical journals are available here. In 2018, Conformis engaged PrecisionEffect and SurveyHealthcareGlobus (SHG) to conduct a study of patient satisfaction with knee implants – Conformis vs. non-Conformis. The results of this third-party study show that 87 percent of the Conformis patients surveyed were highly likely to recommend their knee implant to a friend or colleague, versus only 70 percent of the non-Conformis patients surveyed.
In November 2019, the company announced U.S. Food and Drug Administration clearance of the new 3D-designed Conformis Hip System and the system’s full commercial launch. Similar to the design process for Conformis knee technologies, the Conformis Hip System uses proprietary advanced imaging and design software, to deliver a patient-specific, pre-operative surgical plan with a comprehensive set of iJig instruments and patient-matched implants. The Conformis Hip System iJigs work in conjunction with anatomic landmarks to ensure the proper placement and orientation of the femoral stem, as well as the acetabular cup. In addition, Conformis’ proprietary reamer system provides a single-use, patient-matched reaming solution that delivers efficient and accurate cup orientation to a controlled depth for each surgical case.